Morgan Stanley Genmab A/S Transaction History

Morgan Stanley

$1.39 Trillion
Q4 2024

A detailed history of Morgan Stanley transactions in Genmab A/S stock. As of the latest transaction made, Morgan Stanley holds 2,805,881 shares of GMAB stock, worth $63.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,805,881

Previous 1,640,390 71.05%

Holding current value

$63.6 Million

Previous $40 Million 46.42%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$20.02 - $24.15 $23.3 Million - $28.1 Million	1,165,491 Added 71.05%	2,805,881 $58.6 Million
Q3 2024 Nov 14, 2024	BUY	$23.84 - $28.48 $14.6 Million - $17.4 Million	611,013 Added 59.36%	1,640,390 $40 Million
Q2 2024 Oct 17, 2024	BUY	$25.13 - $30.27 $1.39 Million - $1.68 Million	55,341 Added 5.68%	1,029,377 $25.9 Million
Q2 2024 Aug 14, 2024	BUY	$25.13 - $30.27 $1.39 Million - $1.68 Million	55,341 Added 5.68%	1,029,377 $25.9 Million
Q1 2024 Oct 17, 2024	SELL	$26.43 - $32.77 $1.46 Million - $1.81 Million	-55,341 Reduced 5.38%	974,036 $29.1 Million
Q1 2024 Aug 16, 2024	SELL	$26.43 - $32.77 $3.04 Million - $3.77 Million	-115,061 Reduced 10.56%	974,036 $29.1 Million
Q1 2024 May 15, 2024	SELL	$26.43 - $32.77 $3.04 Million - $3.77 Million	-115,061 Reduced 10.56%	974,036 $29.1 Million
Q4 2023 Aug 16, 2024	BUY	$27.94 - $35.44 $1.67 Million - $2.12 Million	59,720 Added 5.8%	1,089,097 $34.7 Million
Q4 2023 Feb 13, 2024	SELL	$27.94 - $35.44 $319,130 - $404,795	-11,422 Reduced 1.04%	1,089,097 $34.7 Million
Q3 2023 Nov 15, 2023	BUY	$35.27 - $42.24 $3.23 Million - $3.87 Million	91,639 Added 9.08%	1,100,519 $38.8 Million
Q2 2023 Aug 14, 2023	SELL	$37.4 - $42.94 $2.53 Million - $2.91 Million	-67,712 Reduced 6.29%	1,008,880 $38.3 Million
Q1 2023 May 15, 2023	SELL	$34.88 - $43.22 $4.86 Million - $6.02 Million	-139,269 Reduced 11.45%	1,076,592 $40.7 Million
Q4 2022 Feb 14, 2023	BUY	$33.8 - $47.06 $11.8 Million - $16.4 Million	347,824 Added 40.07%	1,215,861 $51.5 Million
Q3 2022 Nov 14, 2022	BUY	$31.52 - $373.61 $4.4 Million - $52.1 Million	139,532 Added 19.15%	868,037 $27.9 Million
Q2 2022 Oct 27, 2022	BUY	$26.83 - $38.57 $16.7 Million - $24 Million	622,902 Added 589.85%	728,505 $23.7 Million
Q2 2022 Aug 15, 2022	BUY	$26.83 - $38.57 $16.7 Million - $24 Million	622,902 Added 589.85%	728,505 $23.7 Million
Q1 2022 Oct 27, 2022	SELL	$30.95 - $39.68 $19.3 Million - $24.7 Million	-622,902 Reduced 85.5%	105,603 $3.82 Million
Q1 2022 May 13, 2022	SELL	$30.95 - $39.68 $1.15 Million - $1.48 Million	-37,231 Reduced 26.07%	105,603 $3.82 Million
Q4 2021 Feb 14, 2022	SELL	$35.87 - $47.12 $1.21 Million - $1.59 Million	-33,650 Reduced 19.07%	142,834 $5.65 Million
Q3 2021 Nov 15, 2021	BUY	$41.55 - $48.72 $7.33 Million - $8.6 Million	176,484 New	176,484 $7.71 Million

Others Institutions Holding GMAB

# of Institutions

248

Shares Held

61.3M

Call Options Held

159K

Put Options Held

38K

View Full List

About GENMAB A/S

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $14.9B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

More about GMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account